BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Dysregulation of apoptosis is a key factor in cancer development and therapeutic resistance.
• Restoring apoptosis balance is a critical goal in cancer therapy.

Purpose of the Study:

• To evaluate the potential of a novel fusion peptide for cancer treatment.
• To assess the peptide's ability to inhibit cancer cell growth and target tumors specifically.

Main Methods:

• In vitro studies using colon, lung, and breast cancer cell lines, along with HEK293 noncancerous cells.
• In vivo studies involving intratumoral injection and systemic administration (tail vein) in nude mice.
• Analysis of apoptosis activation through the mitochondria pathway.

Main Results:

• The fusion peptide demonstrated significant cancer cell growth inhibition in vitro.
• The peptide exhibited cancer specificity, sparing noncancerous HEK293 cells.
• In vivo studies confirmed tumor inhibition and targeted delivery to established tumors without affecting other organs.
• Apoptosis was induced via the mitochondria pathway.

Conclusions:

• The designed fusion peptide, comprising PUMA's BH3 effector domain and TAT/DV3 targeting domains, shows potent anti-cancer activity.
• The peptide is cancer-specific and effectively inhibits tumor growth in vivo.
• This fusion peptide represents a promising candidate for further preclinical evaluation and therapeutic development.